Novartis (VTX:NOVN) Given a CHF 85 Price Target by UBS Group Analysts

Novartis (VTX:NOVN) received a CHF 85 price objective from analysts at UBS Group in a research note issued to investors on Thursday, Borsen Zeitung reports. The firm presently has a “neutral” rating on the stock.

Several other equities research analysts have also recently commented on the company. HSBC set a CHF 83 target price on Novartis and gave the company a “neutral” rating in a research note on Thursday, April 25th. Credit Suisse Group set a CHF 88 target price on Novartis and gave the company a “neutral” rating in a research note on Tuesday, May 28th. Deutsche Bank set a CHF 85 price objective on Novartis and gave the stock a “neutral” rating in a research note on Friday, April 5th. Goldman Sachs Group set a CHF 110 price objective on Novartis and gave the stock a “buy” rating in a research note on Monday, March 25th. Finally, JPMorgan Chase & Co. set a CHF 85 price objective on Novartis and gave the stock a “sell” rating in a research note on Wednesday, April 3rd. Three analysts have rated the stock with a sell rating, six have issued a hold rating and eight have issued a buy rating to the company’s stock. Novartis presently has an average rating of “Hold” and an average target price of CHF 89.18.

Novartis has a 52 week low of CHF 72.45 and a 52 week high of CHF 88.30.

Novartis Company Profile

Novan, Inc, a clinical-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage product candidates include SB204, a topical monotherapy that is in Phase III pivotal clinical trials for the treatment of acne vulgaris; and SB206, a topical antiviral gel, which is in Phase III pivotal trials for the treatment of patients with external genital warts, and Phase II clinical trial for the treatment of molluscum contagiosum.

Read More: Hedge Funds

Analyst Recommendations for Novartis (VTX:NOVN)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.